our SERVICES

find the right Shard capital service for you:

image description

fund Management

fund Management

A range of funds covering diverse investor needs, from fixed income to venture capital

image description

Investment Management

Investment Management

Stockbroking and wealth management services for all investors

image description

Capital markets

Capital markets

Corporate broking, IR, advisory and alternative finance for all corporate capital requirements

image description

institutional broking

institutional broking

Professional broking and investment products for institutions, family offices and professional investors

image description

corporate Capital

corporate Capital

Direct lending and venture capital for a range of small and medium-sized enterprises

spotlight image

In Search of a Matador

Check out our Fixed Income Fund's macro update for this month >
image description

Suir Valley Ventures invests in WarDucks

find out more >

LATEST NEWS

Horizonte Minerals Plc - PDMR Dealing

Horizonte Minerals Plc announces that on 15 September 2017, William Fisher, Non-Executive Director of the Company, purchased 200,000 ordinary shares of 1p each in the capital of the Company (“Ordinary Shares”) at a price of CAD$0.055 per Ordinary Share (the “Purchase”). Following the Purchase, Mr. Fisher is now interested in 1,020,000 Ordinary Shares representing 0.09% of […] Read more

Keras Resources Plc - Calidus Enters Joint Venture with Novo Resources

Keras Resources plc, the AIM listed mineral resource company, is pleased to provide an update following an announcement published by Calidus Resources Limited (‘Calidus’), in which Keras currently holds a 30% interest.  Calidus has announced it has entered into a binding Term Sheet with Novo Resources Corp. (TSX.V:NVO) (‘Novo’) to form a joint venture under […] Read more

Motif Bio - Iclaprim Granted Orphan Drug Designation by US FDA for Staphylococcus Aureus Lung Infections for Cystic Fibrosis Patients

Motif Bio plc, a clinical stage biopharmaceutical company specialising in developing novel antibiotics, announced today that the US Food and Drug Administration (“FDA”) has granted its investigational drug candidate, iclaprim, Orphan Drug Designation for the treatment of Staphylococcus aureus lung infections in patients with cystic fibrosis. Orphan designation grants special status to a drug or biologic under development […] Read more